Development and evaluation of a portable audiometer for high-frequency screening of hearing loss from ototoxicity in homes/clinics

Peter Jacobs, Grayson Silaski, Debra Wilmington, Samuel Gordon, Wendy Helt, Garnett McMillan, Stephen A. Fausti, Marilyn Dille

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Cancer treatment often requires patients to be exposed to drugs that can damage hearing. Drugs such as cisplatin can cause permanent damage to hearing if not detected early. Damage typically occurs first in the more basal regions of the cochlea which are specific for high-frequency (HF) hearing and progresses to more apical regions that are relevant to speech understanding. Monitoring of HF hearing loss can be an effective means for early detection of ototoxicity caused by chemotherapy. Once ototoxicity is detected, the oncology medical team could adjust the drug dosage or switch to medications that are less ototoxic. Telehealth technology may improve access to ototoxicity monitoring. Patients could monitor their own hearing using a device that alerts healthcare professionals in the event of a change in hearing. A portable audiometer is currently not available that is 1) capable of automatic or manual (by an audiologist) operation; 2) designed with precision pure-tone functionality up to 20kHz; and 3) able to remotely transfer health status information to a healthcare professional. This paper describes the design of a technology, the ototoxicity identification (OtoID), that includes a portable audiometer with HF test functionality that meets ANSI/ASA S3.6-2010 standards and is capable of reliably detecting a persons drug-related hearing changes relative to a baseline period (i.e., before ototoxic drugs) using an automated test. The system includes a wireless cellular modem capable of notifying a remote healthcare professional in the event that a significant change in hearing has occurred in the patient. The system was evaluated on test subjects within a sound-proof booth, a noisy hospital ward, and within their homes. Results indicate that the OtoID system can be used by patients to effectively monitor hearing changes remotely within their home or in a hospital ward, ultimately enabling early detection of ototoxicity and potentially avoiding hearing loss.

Original languageEnglish (US)
Article number6237516
Pages (from-to)3097-3103
Number of pages7
JournalIEEE Transactions on Biomedical Engineering
Volume59
Issue number12 PART2
StatePublished - 2012

Fingerprint

Audiometers
Audition
Screening
Oncology
Drug dosage
Chemotherapy
Monitoring
Modems

Keywords

  • Hearing screening
  • high-frequency (HF) audiometry
  • ototoxicity monitoring

ASJC Scopus subject areas

  • Biomedical Engineering

Cite this

Jacobs, P., Silaski, G., Wilmington, D., Gordon, S., Helt, W., McMillan, G., ... Dille, M. (2012). Development and evaluation of a portable audiometer for high-frequency screening of hearing loss from ototoxicity in homes/clinics. IEEE Transactions on Biomedical Engineering, 59(12 PART2), 3097-3103. [6237516].

Development and evaluation of a portable audiometer for high-frequency screening of hearing loss from ototoxicity in homes/clinics. / Jacobs, Peter; Silaski, Grayson; Wilmington, Debra; Gordon, Samuel; Helt, Wendy; McMillan, Garnett; Fausti, Stephen A.; Dille, Marilyn.

In: IEEE Transactions on Biomedical Engineering, Vol. 59, No. 12 PART2, 6237516, 2012, p. 3097-3103.

Research output: Contribution to journalArticle

Jacobs, P, Silaski, G, Wilmington, D, Gordon, S, Helt, W, McMillan, G, Fausti, SA & Dille, M 2012, 'Development and evaluation of a portable audiometer for high-frequency screening of hearing loss from ototoxicity in homes/clinics', IEEE Transactions on Biomedical Engineering, vol. 59, no. 12 PART2, 6237516, pp. 3097-3103.
Jacobs, Peter ; Silaski, Grayson ; Wilmington, Debra ; Gordon, Samuel ; Helt, Wendy ; McMillan, Garnett ; Fausti, Stephen A. ; Dille, Marilyn. / Development and evaluation of a portable audiometer for high-frequency screening of hearing loss from ototoxicity in homes/clinics. In: IEEE Transactions on Biomedical Engineering. 2012 ; Vol. 59, No. 12 PART2. pp. 3097-3103.
@article{5aaa5fc8e0f442d08e946bc036798cae,
title = "Development and evaluation of a portable audiometer for high-frequency screening of hearing loss from ototoxicity in homes/clinics",
abstract = "Cancer treatment often requires patients to be exposed to drugs that can damage hearing. Drugs such as cisplatin can cause permanent damage to hearing if not detected early. Damage typically occurs first in the more basal regions of the cochlea which are specific for high-frequency (HF) hearing and progresses to more apical regions that are relevant to speech understanding. Monitoring of HF hearing loss can be an effective means for early detection of ototoxicity caused by chemotherapy. Once ototoxicity is detected, the oncology medical team could adjust the drug dosage or switch to medications that are less ototoxic. Telehealth technology may improve access to ototoxicity monitoring. Patients could monitor their own hearing using a device that alerts healthcare professionals in the event of a change in hearing. A portable audiometer is currently not available that is 1) capable of automatic or manual (by an audiologist) operation; 2) designed with precision pure-tone functionality up to 20kHz; and 3) able to remotely transfer health status information to a healthcare professional. This paper describes the design of a technology, the ototoxicity identification (OtoID), that includes a portable audiometer with HF test functionality that meets ANSI/ASA S3.6-2010 standards and is capable of reliably detecting a persons drug-related hearing changes relative to a baseline period (i.e., before ototoxic drugs) using an automated test. The system includes a wireless cellular modem capable of notifying a remote healthcare professional in the event that a significant change in hearing has occurred in the patient. The system was evaluated on test subjects within a sound-proof booth, a noisy hospital ward, and within their homes. Results indicate that the OtoID system can be used by patients to effectively monitor hearing changes remotely within their home or in a hospital ward, ultimately enabling early detection of ototoxicity and potentially avoiding hearing loss.",
keywords = "Hearing screening, high-frequency (HF) audiometry, ototoxicity monitoring",
author = "Peter Jacobs and Grayson Silaski and Debra Wilmington and Samuel Gordon and Wendy Helt and Garnett McMillan and Fausti, {Stephen A.} and Marilyn Dille",
year = "2012",
language = "English (US)",
volume = "59",
pages = "3097--3103",
journal = "IEEE Transactions on Biomedical Engineering",
issn = "0018-9294",
publisher = "IEEE Computer Society",
number = "12 PART2",

}

TY - JOUR

T1 - Development and evaluation of a portable audiometer for high-frequency screening of hearing loss from ototoxicity in homes/clinics

AU - Jacobs, Peter

AU - Silaski, Grayson

AU - Wilmington, Debra

AU - Gordon, Samuel

AU - Helt, Wendy

AU - McMillan, Garnett

AU - Fausti, Stephen A.

AU - Dille, Marilyn

PY - 2012

Y1 - 2012

N2 - Cancer treatment often requires patients to be exposed to drugs that can damage hearing. Drugs such as cisplatin can cause permanent damage to hearing if not detected early. Damage typically occurs first in the more basal regions of the cochlea which are specific for high-frequency (HF) hearing and progresses to more apical regions that are relevant to speech understanding. Monitoring of HF hearing loss can be an effective means for early detection of ototoxicity caused by chemotherapy. Once ototoxicity is detected, the oncology medical team could adjust the drug dosage or switch to medications that are less ototoxic. Telehealth technology may improve access to ototoxicity monitoring. Patients could monitor their own hearing using a device that alerts healthcare professionals in the event of a change in hearing. A portable audiometer is currently not available that is 1) capable of automatic or manual (by an audiologist) operation; 2) designed with precision pure-tone functionality up to 20kHz; and 3) able to remotely transfer health status information to a healthcare professional. This paper describes the design of a technology, the ototoxicity identification (OtoID), that includes a portable audiometer with HF test functionality that meets ANSI/ASA S3.6-2010 standards and is capable of reliably detecting a persons drug-related hearing changes relative to a baseline period (i.e., before ototoxic drugs) using an automated test. The system includes a wireless cellular modem capable of notifying a remote healthcare professional in the event that a significant change in hearing has occurred in the patient. The system was evaluated on test subjects within a sound-proof booth, a noisy hospital ward, and within their homes. Results indicate that the OtoID system can be used by patients to effectively monitor hearing changes remotely within their home or in a hospital ward, ultimately enabling early detection of ototoxicity and potentially avoiding hearing loss.

AB - Cancer treatment often requires patients to be exposed to drugs that can damage hearing. Drugs such as cisplatin can cause permanent damage to hearing if not detected early. Damage typically occurs first in the more basal regions of the cochlea which are specific for high-frequency (HF) hearing and progresses to more apical regions that are relevant to speech understanding. Monitoring of HF hearing loss can be an effective means for early detection of ototoxicity caused by chemotherapy. Once ototoxicity is detected, the oncology medical team could adjust the drug dosage or switch to medications that are less ototoxic. Telehealth technology may improve access to ototoxicity monitoring. Patients could monitor their own hearing using a device that alerts healthcare professionals in the event of a change in hearing. A portable audiometer is currently not available that is 1) capable of automatic or manual (by an audiologist) operation; 2) designed with precision pure-tone functionality up to 20kHz; and 3) able to remotely transfer health status information to a healthcare professional. This paper describes the design of a technology, the ototoxicity identification (OtoID), that includes a portable audiometer with HF test functionality that meets ANSI/ASA S3.6-2010 standards and is capable of reliably detecting a persons drug-related hearing changes relative to a baseline period (i.e., before ototoxic drugs) using an automated test. The system includes a wireless cellular modem capable of notifying a remote healthcare professional in the event that a significant change in hearing has occurred in the patient. The system was evaluated on test subjects within a sound-proof booth, a noisy hospital ward, and within their homes. Results indicate that the OtoID system can be used by patients to effectively monitor hearing changes remotely within their home or in a hospital ward, ultimately enabling early detection of ototoxicity and potentially avoiding hearing loss.

KW - Hearing screening

KW - high-frequency (HF) audiometry

KW - ototoxicity monitoring

UR - http://www.scopus.com/inward/record.url?scp=84868220622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868220622&partnerID=8YFLogxK

M3 - Article

C2 - 22801480

AN - SCOPUS:84868220622

VL - 59

SP - 3097

EP - 3103

JO - IEEE Transactions on Biomedical Engineering

JF - IEEE Transactions on Biomedical Engineering

SN - 0018-9294

IS - 12 PART2

M1 - 6237516

ER -